NOVARTIS FTC CONSENT DECREE AIMS TO INCREASE RPR COMPETITIVENESS IN GENE THERAPY; COMBINED CIBA/SANDOZ WOULD HAVE $2.6 BIL. IN U.S. SALES AT BASELINE
Executive Summary
A goal of the Federal Trade Commission's proposed consent decree for the merger of Ciba and Sandoz into Novartis is to establish Rhone-Poulenc Rorer as a viable competitor in the gene therapy field, FTC declared Dec. 17.